Latest News of MRNA
Inflammatix begins trial evaluating mRNA test for patient infection status
By Yahoo! Finance |
1 day ago
Inflammatix is conducting the TIMED trial to evaluate its TriVerity test for rapid diagnosis of infection and sepsis, aiding in antimicrobial therapy decisions. The trial aims to improve patient care ...
Moderna Inc (MRNA) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ...
By Yahoo! Finance |
5 days ago
If the DSMB recommends unblinding due to meeting vaccine efficacy criteria, interim data will be shared. Moderna does not provide guidance on market share but aims for a flu-COVID combination vaccine ...
Moderna (MRNA) Q3 2024 Earnings Call Transcript
By Yahoo! Finance |
6 days ago
The Moderna earnings call discussed financial results, cost savings, COVID vaccine sales, clinical programs, and pipeline updates. The company aims to drive sales, cost efficiency, and vaccine approva...
-
Buy, Sell, Or Hold MRNA Stock?
By Forbes | 6 days agoModerna's stock price dropped by 48% this year but is expected to rebound after strong Q3 results. The company beat revenue estimates due to high Covid-19 vaccine sales. With a promising RSV vaccine a...
-
Moderna and MSD begin trial of mRNA-4157 and KEYTRUDA combination for lung cancer
By Yahoo! Finance | 2 weeks agoModerna and MSD are conducting a Phase III trial, INTerpath-009, to study mRNA-4157 (V940) combined with KEYTRUDA for treating non-small cell lung cancer....
-
Moderna, Inc. (MRNA): Leading the Way in mRNA Vaccines and Respiratory Health
By Yahoo! Finance | 3 weeks agoAnalysts expect earnings to offset election-related market volatility. Regions Wealth Management CIO, Alan McKnight, discussed how the rate cut environment is reflected in earnings. He emphasized posi...
-
A slow start for self-amplifying mRNA vaccines
By Yahoo! Finance | 3 weeks agoThe success of Arcturus Therapeutics was attributed to strategic timing and unique trial opportunities in Vietnam and Japan. The emergence of samRNA technology amid the Covid-19 pandemic offers promis...
-
Is Moderna Inc. (MRNA) the Best QQQ Stock to Buy According to Analysts?
By Yahoo! Finance | 3 weeks agoAnalysts are optimistic about the market's bullish outlook despite earlier recession concerns. Moderna Inc. (NASDAQ:MRNA) is highlighted among the top QQQ stocks to buy, with its promising RNA therape...
-
Moderna, Inc. (MRNA): Worst Performing NASDAQ Stock in 2024
By Yahoo! Finance | 3 weeks agoThe article highlights Moderna, Inc. (NASDAQ: MRNA) as one of the worst-performing NASDAQ stocks in 2024, shedding 49.18% in market value. Despite challenges, Moderna has potential with a strong vacci...
-
mRNA licensing agreements surge 800% amid GSK lawsuits
By Yahoo! Finance | 3 weeks agoThe success of mRNA technology in Covid-19 vaccines has led to an 800% increase in licensing deal values for mRNA-based pharmaceuticals. Major companies are heavily investing in mRNA technology, but r...
-
Anima Biotech's machine learning programme 'reveals new mRNA drug targets'
By Yahoo! Finance | 1 month agoAnima Biotech is using machine learning to explore the role of mRNA in disease, identifying new therapies. Their mRNA Lighting platform screens for molecules targeting disease pathways, with promising...
-
mRNA licensing agreements double with million-dollar deals
By Yahoo! Finance | 1 month agoMessenger RNA (mRNA) technology has surged in pharmaceuticals, with licensing values increasing by 800%....
-
Is Moderna, Inc. (MRNA) the Worst Performing Stock to Buy on the Dip?
By Yahoo! Finance | 1 month agoMarket experts suggest investing in equities amid increased volatility, emphasizing the opportunity to put money in longer-term assets. The US economic environment shows signs of softness, with shifti...
-
Moderna Inc (NASDAQ:MRNA): Jim Cramer Is Disappointed
By Yahoo! Finance | 1 month agoJim Cramer's latest portfolio ranks Moderna Inc 6th, advising to focus on recession-proof stocks during Fed rate cuts. Moderna faces challenges with vaccine competition and public reluctance, projecti...
-
Jim Cramer Says Moderna Inc. (MRNA) 'Has Been A Big Disappointment'
By Yahoo! Finance | 1 month agoThe article discusses Jim Cramer's insights on AI, emphasizing its potential in customer service and healthcare. Moderna Inc. is highlighted for its innovative technology and strong financial performa...